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Abstract
In semicompeting risks problems, nonterminal time-to-event outcomes such as time
to hospital readmission are subject to truncation by death. These settings are of-
ten modeled with illness-death models for the hazards of the terminal and nonterminal
events, but evaluating causal treatment effects with hazard models is problematic due to
conditioning on survival– a post-treatment outcome– that is embedded in the definition
of a hazard. Extending an existing survivor average causal effect (SACE) estimand,
we frame the evaluation of treatment effects in the context of semicompeting risks
with principal stratification and introduce two new causal estimands: the time-varying
survivor average causal effect (TV-SACE) and the restricted mean survivor average
causal effect (RM-SACE). These principal causal effects are defined among units that
would survive regardless of assigned treatment. We adopt a Bayesian estimation pro-
cedure that parameterizes illness-death models for both treatment arms. We outline
a frailty specification that can accommodate within-person correlation between non-
terminal and terminal event times, and we discuss potential avenues for adding model
flexibility. The method is demonstrated in the context of hospital readmission among
late-stage pancreatic cancer patients.
1 Introduction
Survival remains the gold standard for evaluating treatments in high-mortality settings, but
doctors, patients, and policymakers also make decisions based on outcomes related to quality
of the remaining lifespan, e.g., hospitalization, onset of dementia, or loss of independence.
Comparing treatments on the basis of non-mortality time-to-event outcomes is complicated
by the fact that interventions on quality of life can also affect mortality. Death is a “truncat-
ing” or “terminal” event in that it precludes the occurrence of the “nonterminal” event. As a
motivating example, consider a hospital tasked with reducing readmissions among late-stage
cancer patients. Death is a terminal truncating event because its occurrence precludes future
hospitalizations, and a hospital readmission is a nonterminal event which does not truncate
death. Imagine an intervention which increases every individual’s risk of readmission while
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simultaneously harming survival among the patients most at risk for readmission; a naive
analysis may (unfairly) conclude the intervention reduces readmissions on the basis that
fewer patients in that group survive long enough to experience readmission. This danger
stems from a problem known as “truncation by death” and has been addressed in the causal
inference literature using principal stratification (Zhang and Rubin, 2003).
Principal stratification handles truncation by death by defining causal contrasts to be
restricted among the group that would not experience the truncating event under either
treatment at a fixed time point. Initially introduced by Robins (1986) and formalized in
Rubin (2000) and Zhang and Rubin (2003), the traditional survivor average causal effect
(SACE) is the causal effect of the treatment on the truncated (i.e., non-mortality) outcome
among the subpopulation that would survive regardless of treatment assignment. A number
of papers have discussed the nonparametric identifiability conditions and assumptions for the
SACE (Long and Hudgens, 2013; Zhang and Rubin, 2003; Robins, 1986; Tchetgen Tchetgen,
2014). The time point for defining always-survivorship is often implicit, such as “by the end of
the study,” and typically only one such time t is considered. With a time-to-event structure
of both the terminal (truncating) event and the nonterminal event, explicit definition of
causal effects is indexed by both: (1) the time defining the “always survivors,” denoted with
t, and (2) the time interval over which treatment contrasts on the nonterminal event are
evaluated, r. For example, interest may lie in the causal effect on cumulative incidence of
readmission at 30 days post-discharge (r = 30) among patients who would survive under
either treatment at 60 days (t = 60). Examining such quantities across different values of
(r, t) can serve different inferential purposes. We use the term “snapshot causal effect” to
describe survivor causal effects with r = t, where the same point in time is used in the
definition of an “always”-survivor (i.e., t) and the end point of the interval (0, r] over which
treatment effects on the non-mortality outcome are evaluated.
When the truncated outcome is time-to-event, estimating the SACE at a single t can be
problematic. First, providing one snapshot effect does not give decisionmakers information
about the sensitivity of conclusions to the (possibly arbitrary) choice of t. If an intervention
has different short- and long-term impacts, snapshot effects will provide a mixed or incom-
plete picture. More importantly, they do not account for the fact that timing matters for the
nonterminal event. With hospital readmission, being hospitalized earlier may lead to more
total hospitalizations. Hospitalization could also accelerate death, if the post-readmission
risk of death is higher. In other contexts – such as the onset of dementia – an earlier occur-
rence of the nonterminal event means more time spent in an unfavorable state, even if total
lifespan remains unaffected. These concerns motivate the development of principal strat-
ification methods that explicitly account for the time-to-event nature of the nonterminal
outcome.
Others have partially grappled with principal stratifications defined over time. For ex-
ample, methods exist for treatment noncompliance in longitudinal contexts (Lin et al., 2008;
Dai et al., 2012). But unlike treatment compliance status, which can vary over time arbi-
trarily, death at t under either treatment condition necessarily precludes membership in an
always-alive state at t′ > t. Defining strata on the basis of survival is also closely linked to
principal strata generated by other continuously-scaled quantities (Schwartz et al., 2011).
Continuous variables can, in principle, create an infinite number of groups. Collapsing these
into meaningful subpopulations for principal stratum causal effects is difficult and further
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complicated by problems of partial identifiability. Examples of continuous variables used
to define principal strata include continuous measures of compliance (Jin and Rubin, 2008;
Bartolucci and Grilli, 2011) and distance from a treatment location (Frangakis et al., 2007).
In the survival analysis literature, the problem of nonterminal time-to-event outcomes
which may be truncated by terminal events is referred to as semicompeting risks because
the terminal event acts as a competing risk for the nonterminal event, but the reverse is
not true(Fine et al., 2001). Models which accommodate this semicompeting risks structure
have been applied to a wide range of settings, including hospital readmission (Lee et al.,
2015), cancer recurrence (Xu et al., 2010), career advancement (Pan and Gastwirth, 2013),
and subscription product upgrades (Chen et al., 2017). Shared subject- and/or cluster-
specific random effects, termed “frailties,” allow for correlation between event times that
is induced by unmeasured factors (Xu et al., 2010). Such models are typically constructed
on the hazard scale and account for truncation by removing individuals from nonterminal
risk sets after the time of their observed terminal event; this removal is akin to what occurs
with cause-specific hazards in competing risks problems. Joint modelling of the time-to-
event outcomes is used to describe cumulative incidences or hazard-based predictive models
(Lee et al., 2015). Analyses of semicompeting risks emanating from the survival analysis
literature typically do not focus explicitly on causal inference for treatment effects. Instead,
these analyses estimate hazard ratios, which suffer from known limitations when the goal is
causal inference (Hernan, 2010).
This paper addresses a gap in the literature by adapting existing semicompeting risks
models and anchoring them to a principal stratification framework for the purpose of drawing
causal inferences. We make four main contributions to the existing literature. First, we
propose a framework for principal strata defined by a continuous time-to-event truncating
variable, such as death time. Second, we motivate and define two new causal estimands
for truncated time-to-event outcomes. Third, we describe a density factorization which is
innovative for principal stratification problems and that allows for explicit links to (non-
causal) semicompeting risks models. Lastly, a Bayesian estimation procedure is provided
with accompanying software.
2 A potential outcomes approach for semicompeting
risks data
2.1 Notation
Consider the evaluation of a binary intervention Z (0=control, 1=treated), where interest
lies in its effect on the times to a nonterminal event, R, and a terminal event, T , the occur-
rence of which may leave R ill defined. We continue with the motivating setting of late-stage
cancer care, where Z is an intervention intended to reduce hospital readmission among re-
cently discharged patients, R is the time to hospital readmission, and T is the time to death.
The occurrence of death leaves future readmission undefined. Using the potential outcomes
framework, let Ri(z) and Ti(z) denote the potential event times for readmission and death
for person i, respectively, that would occur if the person were treated with Z = z. One or
both of these events may be right censored by the potential censoring time Ci(z). If death
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occurs without readmission, we set Ri(z) to be R¯, a non-real value. The observed times are
Y Ri = min(Ri(Zi), Ti(Zi), Ci(z)) and Y
T
i = min(Ti(Zi), Ci(z)), where min
(
R¯, x
)
is defined to
be x for any real x. The nonterminal event indicator δRi = 1
(
Y Ri = Ri(Zi)
)
is one if the non-
terminal event is observed to occur and zero otherwise. The analogous death event indicator
is δTi = 1(Y
T
i = Ti(Zi)). The set of covariates available at baseline, denoted by X, may
consist of confounders, predictors of censoring, and measured baseline predictors of either
event type. Together, the observed data for individual i is Oi = (Y
R
i , δ
R
i , Y
T
i , δ
T
i ,X i, Zi).
2.1.1 Principal stratification for continuous time
A principal stratification is a partition of the population into subpopulations defined by joint
values of the potential outcomes under all treatment conditions. Our basic principal strata
are defined by the pair of potential death times (Ti(0), Ti(1)). Since potential outcomes are
not affected by treatment, stratifications based on the basic principal strata – and unions of
these strata – exist prior to treatment assignment and can play a role similar to covariates.
While the basic principal strata describe a unit’s survival experience under both treatments
across the entire time scale, it is useful to derive related quantities. For any t, let Vi(t)
denote the time-varying principal state (Lin et al., 2008; Dai et al., 2012) implied by the
basic principal strata:
Vi(t) =

AA if Ti(0) > t, Ti(1) > t
TK if Ti(0) > t, Ti(1) ≤ t
CK if Ti(0) ≤ t, Ti(1) > t
DD if Ti(0) ≤ t, Ti(1) ≤ t.
The value of Vi(t) represents a union of basic principal strata, depending on whether the
individual is alive at t in both arms (AA), alive only under treatment (CK) or control (TK),
or dead under both (DD). In the context of hospital readmission for cancer patients, we
may be interested in readmission differences among the “always-alive” at 30 days, i.e., {i :
Vi(30) = AA}, as well as the net difference in 30-day survival probabilities P (V (30) = TK)−
P (V (30) = CK).
The set of individuals with Vi(t) = AA can also be viewed as a cohort with a well-defined
and time-varying nonterminal event causal contrast function on interval (0, t). For various
t, we can define survivorship cohorts, denoted by At:
At = {i : min (Ti(0), Ti(1)) > t} = {i : Vi(t) = AA}
We note that At′ ⊆ At for t′ > t. In the context of hospital readmission, A90 refers to the
cohort of patients who would survive at least 90 days regardless of treatment assignment.
Like the principal states, these principal strata are defined solely in terms of potential ter-
minal event times. Within a cohort At, there can be no treatment effect on survival during
the interval (0, t); this fact ensures the time at risk for the nonterminal event is the same
under both treatment and control conditions.
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2.2 Causal estimands for semicompeting risks
2.2.1 The time-varying survivor average causal effect (TV-SACE)
On the cumulative incidence scale, the existing “snapshot” survivor average causal effect is
SACE(t) =P (R(1) < t|V (t) = AA)− P (R(0) < t|V (t) = AA) . (1)
As previously discussed, snapshot estimands do not describe time-varying effects for any well-
defined population. When they are estimated at a single time point, as is typically done, it
is also unclear how sensitive conclusions are to the choice of t. To address these limitations,
we define a new quantity, the time-varying survivor average causal effect (TV-SACE). This
estimand is a function taking two arguments r and t, and it conveys the difference in the
cumulative incidence of nonterminal events by time r among the group that survives past
t > r regardless of assigned treatment:
TV -SACE(r, t) = P (R(1) < r|V (t) = AA)− P (R(0) < r|V (t) = AA) . (2)
The TV-SACE captures the causal effect of Z on R that has manifested by time r, among
the always-survivors at t. For example, hospitals may be interested in comparing 30-day
(r = 30) and 90-day (r = 90) readmission rates among the cancer patients always-surviving
at least 90 days post-discharge (t = 90). When r = t, the TV -SACE(r, t) of Equation 2
coincides with the SACE(t) as defined in Equation 1.
The joint indexing of TV -SACE(r, t) by both r and t is essential for characterizing
causal effects. For a fixed t, the function TV -SACE(r, t) (as a function of r) is a time-
varying causal effect within the At cohort. It describes the accumulation of benefit causally
attributable to treatment among the well-defined – if latent – cohort. The shapes of these
curves for different t reveal whether treatment effects steadily accrue or decay with time
within the cohorts, and describe how the effect on the nonterminal outcome varies across
subpopulations with different underlying risks of death.
Importantly, viewing TV -SACE(r, t) as a function of t does not characterize a time-
varying causal effect, but a function of snapshot effects, each defined within a different At
cohort. It does not represent a causal contrast varying over time in any static population,
but the shape of the function Q(t) = TV -SACE(t, t) has implications for study design as
well as for the interpretation of results from any single study. If the population’s underlying
Q(t) is believed to take on substantively different values over a range of relevant t, any snap-
shot Q(t) gives an incomplete picture, and researchers should plan to estimate time-varying
effects. Estimates of Q(t) also give important information about the expected consistency
of conclusions from studies estimating snapshot effects at different times. In essence, Q(t)
captures the sensitivity of causal effect estimation – in both sign and magnitude – to the
moment in time used to define the always-survivorship group.
2.2.2 The restricted mean survivor average causal effect (RM-SACE)
Another causal estimand is a variation of the the restricted mean survival time (RMST)
and captures the length of the delay in the nonterminal event among always-survivors. This
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effect may be particularly relevant if the nonterminal event represents a permanent state
change, such as the onset of irreversible dementia.
RM -SACE(r, t) = E [min(R(1), r)|V (t) = AA]− E [min(R(0), r)|V (t) = AA]
In the context of preventing hospital readmission, the RM -SACE(r, t) captures how
much expected hospitalization-free time the treatment causes one to accumulate by time r,
defined among the always-survivors At. Within the cohort At, RM -SACE(r, t) describes
the timing of benefit accrual. If, within At, the effect of treatment on the nonterminal events
arises solely by delaying early events, the benefit accrues quickly and RM -SACE(r, t) even-
tually levels off as r increases. If different survivorship cohorts have dramatically different
curves, then the effect on the nonterminal event is heterogeneous with respect to the under-
lying risk of death.
Just as with Q(t), the function M(t) = RM -SACE(t, t) conveys the sensitivity of the
snapshot version to the choice of t. If M(t) increases steadily, the choice of t matters greatly,
and reporting RM -SACE(t, t) for only a single time point understates the total impact of
the treatment on delaying the nonterminal event. On the other hand, if M(t) levels off at
some t∗, then any benefits attributable to treatment can be fully captured by an estimate of
M(t∗).
2.3 Structural assumptions
We now review a set of assumptions essential to our estimation strategy for TV -SACE(r, t)
and RM -SACE(r, t). For clarity, our exposition focuses on non-recurrent nonterminal
events, where any individual who experiences the nonterminal event is no longer at risk
for that event. For nonterminal events which are non-permanent and that in principal could
recur – like a second hospital readmission – the proposed framework may still be relevant
with careful definition of the nonterminal event (e.g., time to first readmission).
Assumption 1. Consistency of potential outcomes.
Ri =ZiRi(1) + (1− Zi)Ri(0)
Ti =ZiTi(1) + (1− Zi)Ti(0)
Consistency is a standard assumption throughout the causal inference literature which
connects observables R and T to their corresponding potential outcomes. Briefly, the treat-
ment is well-defined such that there are no hidden variations within treatment level (Rubin,
1990).
Assumption 2. Conditional exchangeability (no unmeasured confounding).
The observed treatment assignment does not depend on the potential outcomes after account-
ing for the set of measured covariates X.
(R(z), T (z)) ⊥ Z ∣∣ X for z ∈ {0, 1}
In a randomized trial, this assumption holds by design since treatment assignment is inde-
pendent of all measured and unmeasured variables. For observational settings, interpreting
effect estimates as causal effects requires a sufficiently comprehensive X.
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Assumption 3. Shared, non-informative censoring of event times.
The potential censoring times are shared (i.e., Ci ≡ Ci(0) = Ci(1)). Furthermore, the vector
of potential censoring times C is conditionally independent of all potential event times.
(R(0), T (0), R(1), T (1)) ⊥ C∣∣X
Non-informative censoring is required for the consistent estimation of cumulative distri-
bution functions. With administrative censoring, this assumption is satisfied by design.
2.4 Connection to traditional semicompeting risks models
We state a key simplifying assumption that builds a bridge to the semicompeting risks
literature. With closely related nonterminal and terminal event processes, it is unrealistic
to assume that any measured baseline set X will contain all sources of dependence between
potential event times in (R(0), R(1), T (0), T (1)). However, if the cause of the dependence
is baseline heterogeneity in the patient population, it may be reasonable to assume that
baseline factors can be summarized by a one-dimensional subject-specific latent trait γi. As
with any random effect, γi cannot adjust for unmeasured confounding. However, γi can
be used to model sources of dependence in event times across treatment arms which are
independent of the treatment assignment mechanism (i.e., unmeasured predictors).
Assumption 4. Independence of potential outcomes conditional on covariates and latent
frailty.
Potential nonterminal and terminal event times under each treatment are conditionally in-
dependent conditional on X and an individual-level latent trait γ.
(R(0), T (0)) ⊥ (R(1), T (1)) |γ,X
Assumption 4 suggests a factorization of the joint density of the four potential outcomes
R(0), R(1), T (0), and T (1) that is unusual within the principal stratification literature. Tra-
ditional model-based principal stratification approaches build a model for stratum member-
ship given covariates (the “S-model”), and a model for the joint distribution of the potential
outcomes conditional on the principal strata and covariates (the “Y-model”) (Schwartz et al.,
2011). Instead, we choose an alternative factorization, shown in Equation 3, which further
simplifies to Equation 4 under Assumption 4.
f (R(0), R(1), T (0), T (1)|X, γ) =f (R(0), T (0)|X, γ) f (R(1), T (1)|R(0), T (0),X, γ) (3)
=f (R(0), T (0)|X, γ) f (R(1), T (1)|X, γ) (4)
This arrangement makes it easy to enforce that Ti(z) must exceed Ri(z) whenever the nonter-
minal event occurs (i.e., Ri(z) ∈ R+). We can also leverage existing illness-death transition
models from the semicompeting risks literature to obtain a general form of the likelihood.
2.5 Likelihood
Within a single treatment condition, the semicompeting risks structure of the potential
outcomes R(z) and T (z) can be seen as an illness-death transition model characterizing
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transitions among the event-free (“healthy”), nonterminal only (“ill”), and post-terminal
(“dead”) states. Hazards can be defined for the three types of event transitions: (1) healthy-
ill, (2), healthy-dead, and (3) ill-dead.
λz1(r) = lim
∆→0
P
(
Y R(z) ∈ [r, r + ∆)|Y R(z) ≥ r, Y T (z) ≥ r)
∆
λz2(t) = lim
∆→0
P
(
Y T (z) ∈ [t, t+ ∆)|Y R(z) ≥ t, Y T (z) ≥ t)
∆
λz2(t|r) = lim
∆→0
P
(
Y T (z) ∈ [t, t+ ∆)|Y R(z) = r, Y T (z) ≥ r)
∆
The treatment arm-specific hazards conditional on covariates are denoted λz1(t|xi, γi,θ),
λz2(t|xi, γi,θ), and λz3(t|r,xi, γi,θ), where θ is a vector of unknown parameters. With cumu-
lative hazard Λzj(t|·) =
∫ t
0
λzj(u|·)du, the observed data likelihood conditional on Oi is given
by
Lc =
n∏
i=1
(
[λZi1 (y
R
i |xi, γi,θ)]δ
R
i [λZi2 (y
R
i |xi, γi,θ)]δ
T
i (1−δRi )[λZi3 (y
T
i |yRi ,xi, γi,θ)]δ
T
i δ
R
i
× exp{−ΛZi1 (yRi |xi, γi,θ)− ΛZi2 (yRi |xi, γi,θ)− ΛZi3 (yTi |yRi ,xi, γi,θ)}) (5)
If the frailties are included as unknown parameters in an expanded parameter set θ∗ = (θ,γ)
for γ = (γ1, . . . , γn)
′, the dimension of the parameter space is large and grows linearly with
n, rendering estimation impracticable for large data sets. For computational efficiency and
scalability, we use the marginalized likelihood Lm =
∫ Lcf(γ)dγ rather than the conditional
likelihood in our estimation algorithm. For selected choices of f(γ), the form of Lm can be
obtained analytically, but numerical integration within the MCMC can be used to accom-
modate arbitrary f(γ). Computationally feasible estimation strategies are the focus of the
next section.
3 Bayesian model-based estimation of causal effects
3.1 Identifiability in the Bayesian framework
We propose a Bayesian approach anchored to illness-death models for state transitions.
Note that the likelihood in Section 2.5 does not support point identifiability of the principal
stratum causal effects, a problem which also arises with the more traditional (i.e., snapshot)
SACE (Long and Hudgens, 2013). This motivates our use of a Bayesian estimation procedure.
In addition to the ability to handle large amount of missing data (including unobserved
potential outcomes) in much the same way as unknown parameters, the Bayesian procedure
with proper prior distributions will yield proper posterior inference, even in the face of flat
portions of the likelihood. In these instances, some of the unknown parameters in θ are
only “partially identified”: even with infinite amounts of data, the posterior distribution
converges to a non-degenerate distribution over a range of possible values that is smaller
than that specified in the prior, but not equal to a single point (Gustafson, 2010).
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3.2 Implementation with parametric illness-death models
In this paper we focus on hazards parameterized using Weibull regression models for each of
the six possible transitions. Although alternative specifications are possible, we elect to use
a semi-Markov model for the terminal event after the occurrence of the nonterminal event
(i.e., for t > Ri(z), the terminal event hazard at t depends on Ri(z) only through (t−Ri(z))
(Lee et al., 2015). For z ∈ {0, 1} and j ∈ {1, 2, 3}, the Weibull shape for transition j under
Z = z is denoted αzj , and the baseline hazard rate is κ
z
j , giving hazard equations:
λz1(t|xi, γi,θ) = γiκz1αz1tα
z
1−1 exp {x′iβz1}
λz2(t|xi, γi,θ) = γiκz2αz2tα
z
2−1 exp {x′iβz2}
λz3(t|ri(z),xi, γi,θ) = γiκz3αz3(t− ri(z))α
z
3−1 exp {x′iβz3} for t > ri(z)
The complete parameter vector for the above model specification is θ = (α,β,κ, σ) for
α = (α01, . . . , α
1
3), κ = (κ
0
1, . . . , κ
1
3), and β = (β
0
1, . . . ,β
1
3)
′. For computational convenience
we suppose that the independent subject-specific frailties γi arise from a gamma distribution
constrained to have a mean of 1 with unknown variance σ. This parametric assumption
allows the marginal likelihood to be computed analytically, regardless of the specific models
used for the baseline hazards. Equation 6 gives the likelihood marginalizing over independent
gamma-distributed frailties
Lm =
n∏
i=1
[
(1 + σ)δ
R
i δ
T
i [λZi1 (y
R
i |xi,θ)]δ
R
i [λZi2 (y
R
i |xi,θ)]δ
T
i (1−δRi )[λZi3 (y
T
i |yRi ,xi,θ)]δ
T
i δ
R
i
×
(
1 + σ
[
ΛZi1 (y
R
i |xi,θ) + ΛZi2 (yRi |xi,θ) + ΛZi3 (yTi |yRi ,xi,θ)
])−(1/σ+δRi +δTi )]
(6)
where λzj(t|xi,θ) = λzj(t|xi, γi = 1,θ) is a reference level transition hazard for j ∈ {1, 2, 3}.
Details of this marginalization can be found in the Web Appendix.
As with any Bayesian procedure, prior distributions must be placed on all unknown
parameters. For the frailty variance σ, we suggest eliciting weakly informative priors from
subject matter experts since we encountered convergence problems with dispersed starting
values and vague priors (e.g., the Gamma(0.7, 0.7) prior on the precision σ−1 suggested by
Lee et al. (2015)). Priors for other components of θ are intended to be weakly informative;
details can be found in the Web Appendix. Analyses can be performed with different prior
distributions to gauge sensitivity of substantive conclusions to the choice of prior.
3.3 Estimation algorithm
The estimation procedure for the causal quantities can be summarized in four steps: (1)
estimating regression model coefficients θ using MCMC, (2) sampling latent frailties γ con-
ditional on the posterior of θ, (3) imputing missing factual and counterfactual outcomes
conditional on the posterior of (θ,γ), and (4) using imputed potential outcomes to calculate
causal estimands of interest.
We obtain posterior samples of θ with a modified Hamiltonian Monte Carlo No-U-Turn
Sampler in Stan using the marginalized form of the likelihood. Suppose there are B post-
warmup MCMC parameter samples θ(1), . . . ,θ(B). The closed form of γi|θ is a gamma
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distribution (see Web Appendix), which facilitates sampling from the posterior for γ. Using
these B posterior samples of (θ,γ), we can draw from the posterior predictive distribution
of the full set of potential outcomes (R(Z), T (Z), R(1− Z), T (1− Z)). Full details of the
imputation procedure can be found in the Web Appendix.
The final step of finite sample causal inference is straightforward once all potential out-
comes have been either directly observed or imputed. For a sequence of K time points
t1, . . . , tK with tK ≤ maxi(yRi ) dictated by the scientific question, the principal state vec-
tor V (tk) is a deterministic function of T (0) and T (1). For MCMC iteration b, denote
the principal state for person i at time point k by Vi(tk)
(b). Given T (0)(b) and T (1)(b), let∣∣∣A(b)tk ∣∣∣ be the number in the always-alive state at tk (i.e., ∑ni=1 1 (Vi(tk)(b) = AA)). For any
r ∈ {t1, . . . , tk}, a posterior draw of the sample time-varying survivor average causal effect
is given by
TV -SACE(r, tk)
(b) =
∣∣∣A(b)tk ∣∣∣−1 ∑
i:Vi(tk)(b)=AA
[
1
(
Ri(1)
(b) < r
)− 1 (Ri(0)(b) < r)]
Similarly, the bth posterior draw of the sample restricted mean survivor average effect is
RM -SACE(r, tk)
(b) =
∣∣∣A(b)tk ∣∣∣−1 ∑
i:Vi(tk)(b)=AA
[
min
(
Ri(1)
(b), r
)−min (Ri(0)(b), r)]
As with any posterior sample, the B draws of TV -SACE(r, tk)
(b) or RM -SACE(r, tk)
(b) can
be summarized using the means, medians, or quantile-based credible intervals for each (r, tk)
pair. Finally, given our reliance on modeling assumptions, some diagnostics are in order.
3.4 Discrepancy measures for posterior predictive checking
Certain aspects of the model fit can be assessed by performing posterior predictive checks,
which generate replicate data sets
(
Xrep, Zrep, Y R,rep, Y T,rep, δR,rep, δT,rep
)
. Discrepancy mea-
sures are test statistics compared across the observed and replicate data sets, with corre-
sponding p-values near 0 or 1 indicating that the assumed data generating process does not
explain the data well (Gelman et al., 2013). While assumptions such as unconfoundedness
remain inherently untestable, these metrics can identify poor model fit to observed features
of the data as well as some characteristics of unobserved.
We propose three discrepancy measures intended to gauge whether causal conclusions
are threatened by serious model misspecification. The first set, TKM,z,t for z ∈ {0, 1}, are
based on the marginal Kaplan-Meier estimates of survival within each treatment group and
operate as more traditional goodness of fit tests. These measures deal exclusively with
potentially-observable information: survival probabilities P (T (z) > t) among those patients
observed with Z = z. In contrast, another metric (TKS) employs Kolmogorov-Smirnov
tests to compare the distribution of (imputed) in-sample frailties relative to the distribution
implied by the assumed data generation process. Because frailties are inherently latent,
TKS can provide evidence of misfit within an unobserved part of the model. A final class
of metrics, TAA,t, highlight the degree to which frailty misspecification changes estimates of
the size of the always-alive stratum. While TKM,0 and TKM,1 are more traditional model fit
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assessments, the TKS and TAA discrepancy metrics are different in that their calculation relies
on predictions of quantities which are not strictly observed (i.e., involving the dependence
between outcomes across treatment conditions). Details and implementation algorithms
for the TKM,z,t, TKS, and TAA,t metrics are available in the Web Appendix. We provide a
complete implementation of steps for parameter sampling, posterior prediction, causal effect
estimation, and discrepancy measure calculation through the rsemicompstan R package
available on GitHub at github.com/lcomm/rsemicompstan.
4 Evaluation of supportive home care effects on mor-
tality and hospital readmission among pancreatic can-
cer patients
4.1 Medicare Part A pancreatic cancer readmission data
We demonstrate our method in an analysis of hospital readmission using a data set of 12,091
newly diagnosed pancreatic cancer patients in the United States. The initial sample consisted
of 17,685 Medicare Part A enrollees in California from 2000 to 2012 who were hospitalized
and later discharged with a diagnosis of pancreatic cancer. DWe limited our analysis to the
12,091 patients who were healthy enough to be discharged to home (i.e., not hospice or a
skilled nursing facility). The baseline t = 0 was set to the date of discharge from the index
hospitalization during which the cancer was diagnosed. Hospital readmission as a proxy for
quality of care usually focuses on a short window after the index hospitalization. To focus on
these short-term effects, administrative censoring was applied at 90 days. More information
can be found in Lee et al. (2015).
The scientific question of interest is whether in-home supportive care leads to lower rates
of hospital readmission than discharging to home without additional support. Of the 12,091
patients discharged to home, 3,140 (26%) were sent home with supportive care. A major
concern was that patients discharged without care would be systematically healthier than
those discharged with support, presenting a strong threat of confounding. To reduce the
dependence of model-based confounding adjustment, a logistic regression propensity score
model for the receipt of home care was constructed using all available baseline covariates:
non-White race, age, dichotomized Charleston-Deyo comorbidity score, admission route,
and length of stay during index hospitalization. Estimated propensity scores used to match
(without replacement) 3,140 of the 8,951 patients discharged without care for comparison
with those receiving supportive care (Ho et al., 2007). Thus, inference is confined to causal
effects among the population represented by those receiving supportive care, i.e., average
effects on the “treated,” representing the effect of supportive care among those who actually
received it.
Hazard regression models included the same covariate set, with all covariates mean cen-
tered. Age and length of stay were scaled to have a standard deviation of 1 to facilitate
specification of priors for the coefficients. As proposed in Section 3.3, we adopted Weibull
transition hazards with a semi-Markov specification for the post-readmission hazard of death.
Adjustment covariate effects β = (β01, . . . ,β
1
3)
′, the baseline hazard κ = (κ01, . . . , κ
1
3)
′, and
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Figure 1: Posterior mean survival curves among newly diagnosed pancreatic cancer patients
discharged home, with supportive care (z = 1) and without (z = 0), with the corresponding
implications for always-alive principal stratum size (A) and posterior mean population com-
position of always-alive (AA), treatment-killed (TK), control-killed (CK), and doubly dead
(DD) principal states (B)
Weibull shape parameters α = (α01, . . . , α
1
3)
′ were allowed to freely vary across treatment
arm and transition type. Prior distributions were specified as in Section 3.2.
Posterior draws of θ = (α,κ,β) were obtained from 4 chains of 4,000 MCMC iterations
each, with the first 3,000 iterations removed as warmup. Gelman-Rubin potential scale
reduction factors Rˆ and effective sample sizes were calculated for each parameter (Gelman
et al., 2013; Carpenter et al., 2017). Using the procedure outlined in Section 3.3, posterior
draws of the frailties and missing potential outcomes were obtained using the 4,000 post-
warmup samples of θ.
4.2 Readmission and mortality results
All Gelman-Rubin Rˆ values were below 1.01, indicating good mixing of the chains, and the
minimum effective sample size across all parameters was 2,455.
Part A of Figure 1 shows the posterior mean survival curves for each treatment group and
their implications for posterior mean size of the always-survivor subpopulation. The fastest-
declining survival curve, shown in green, is the in-sample average of time to first potential
death (i.e., min (Ti(0), Ti(1))); the “survival” S(t) equals P (V (t) = AA). The other two
curves in Part A show the mean S(t) for the counterfactual survival probabilities if everyone
in the (matched) sample had been treated with extra care (z = 1, in navy) or discharged
home without extra care (z = 0, in orange). Based on these covariate-adjusted survival
curves, the treatment of receiving additional support at home leads to reduced lifespan
across the 90 days, i.e., P (T (0) > t) > P (T (1) > t) for t < 90. For all curves, uncertainty
increases with time because of the decreasing number of subjects used to estimate survival.
Relative to the T (z) survival curves, there is additional uncertainty in the P (V (t) = AA)
estimates due to uncertainty in σ and γ.
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Part B of Figure 1 shows the posterior mean proportion of the population in each principal
state {AA, TK,CK,DD} over time. For small t, nearly the entire population is in the AA
state because few deaths are observed or imputed under z ∈ {0, 1}. With time, more deaths
accumulate among patients discharged home with support, leading to a greater proportion
of the population in the TK state than the CK state. The population fractions in TK and
CK stay relatively constant after approximately day 45, suggesting that most patients who
would die only if discharged to one of the conditions will do so relatively early in the 90-day
time frame. The overall effect is that depletion of the always-alive principal stratum occurs
more during the early part of the 90-day window.
4.2.1 Population-level causal effects
Applying principal stratification to semicompeting risks data allows us to characterize treat-
ment effects among subgroups defined by always-survivorship through various t (i.e., At
for various t). Part A of Figure 2 shows posterior means for TV -SACE(r, t) for 5 always-
survivor cohorts At: t ∈ {15, 30, 45, 60, 90}. In all cohorts, support leads to greater incidence
of hospital readmission. In the first days after discharge from the index hospitalization, the
healthier, longer-surviving cohorts like A90 have treatment effects on readmission rates which
are similar to cohorts with less stringent survivorship requirements (e.g., A15). However, ef-
fects among the longer-surviving cohorts begin to level off over time. This may point to a
heterogeneity in reasons requiring a readmission; that is, readmissions occurring in the first
week or so after diagnosis may be caused by a different mixture of proximate causes than
the admissions during the rest of the 90 days. Additional contact with medical personnel
at home may also speed the detection of the early complications warranting readmission.
However, given the poorer survival of the supported group, this could also be the result of
residual uncontrolled confounding by indication if, after adjusting for X and the propensity
score preprocessing, those receiving supportive care remain at systematically higher risk for
readmission.
From a policy perspective, we may be interested in the consistency of snapshots effect
across time. If the estimated effects on readmission vary dramatically depending on t, then
policymakers must be more careful when synthesizing evidence across studies offering snap-
shots from different t. Plot B of Figure 2 shows estimated curves of Q(t) = TV -SACE(t, t)
across t, with each of the 500 lines derived from a representative posterior draw of θ. The
color of the lines at each t gives the proportion of the study population in the always-alive
state at t according to that set of posterior predictive potential outcome samples. The shape
suggests that, for the cumulative incidence scale, there is no natural time point for evaluating
the causal effect of discharge support on hospital readmission because Q(t) never completely
levels off. However, the direction of the effect (i.e., higher cumulative incidence in the group
discharged with care) is largely consistent over time.
Like the time-varying survivor average causal effect, the restricted mean effects also sug-
gest that being discharged home with support increases readmissions. Part C of Figure 2
shows the within-cohort accumulation of readmission-free days attributable to being dis-
charged with support. Because the accumulation is negative, this finding is consistent with
faster and ultimately greater cumulative incidence of readmission among the treated (i.e.,
supported) group. In part due to the natural ceiling of t in the definition of the restricted
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Figure 2: Estimated time-varying (TV -SACE) and restricted mean (RM -SACE) survivor
average causal effects of home care (vs. no additional care at home) on the cumulative
incidence of hospital readmission among 6,280 newly diagnosed late-stage pancreatic cancer
patients
mean, the estimated snapshot function M(t) = RM -SACE(t, t) in Part D of Figure 2
steadily grows in magnitude over the course of the 90 days.
4.2.2 Implications for individual-level decisionmaking
The posterior distribution for frailty variance σ shows substantial remaining variability in
prognosis that is not explained by the covariates included in the models, with a mean of
1.44 (95% CI: 1.25, 1.65). To put this estimate into perspective, σ = 1.44 corresponds to
patients in the 90th percentile of the latent frailty experiencing event hazards that are 55
times the hazards for comparable patients in the 10th percentile. Relative to the variation in
prognoses explained by predictive covariates, large values for σ pose additional difficulties for
tailored decisionmaking. Nevertheless, covariate-specific posterior predictions may be used
to differentiate treatment recommendations.
In contrast to policymaking motivated by population effects, decisionmakers choosing for
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Table 1: Posterior predictive means for principal state probabilities and principal stratum
causal effects for new patients of two covariate patterns
Principal State
Probabilities at t1
If always-alive,
causal effect of being
discharged to home with support
(vs. without)
Patient characteristics Latent health2 Day t AA CK TK
Difference in readmission
incidence by t
Additional readmission-free
days accumulated by t
Nonwhite male aged 85,
average comorbidity score
and hospital length of stay
Frail 30 0.181 0.140 0.383 -0.173 5.444
90 0.003 0.013 0.159 -0.040 14.170
Average 30 0.560 0.122 0.261 -0.128 2.821
90 0.107 0.106 0.394 -0.101 12.116
Healthy 30 0.979 0.007 0.014 -0.009 0.152
90 0.916 0.026 0.056 -0.018 1.000
White female aged 65,
average comorbidity score
and hospital length of stay
Frail 30 0.520 0.157 0.248 -0.024 1.387
90 0.110 0.157 0.301 0.000 1.793
Average 30 0.821 0.063 0.107 -0.030 0.966
90 0.449 0.162 0.286 0.002 1.470
Healthy 30 0.995 0.001 0.004 -0.003 0.076
90 0.979 0.006 0.015 0.000 0.200
1 Always-alive (AA), dead only under control (CK), and dead only under treatment (TK)
2 Frail and healthy correspond to the 90th and 10th percentiles of γ, while average health corresponds to γ = 1
a single individual may be interested in the extent to which that individual’s readmission
prospects depend on treatment, as well as treatment’s impact on survival. Table 1 gives
examples of tailored prognoses for a two selected covariate patterns. If more information is
known about the underlying health state than the covariates used in the initial analysis –
say, the individual can infer they are healthier than average patients with similar observed
covariates – these prognoses can be further personalized.
As expected, the posterior predictive state probabilities show that – for comparable levels
of underlying frailness – a younger White woman is much more likely to be in the always-alive
state at 90 days than an older non-White man with the same comorbidity score and duration
of index hospitalization. However, the magnitude of this survival advantage varies greatly.
For an individuals in the 10th or 90th percentile of latent health (i.e., the 90th or 10th percentile
for γ), the difference in the probability of being always-alive at t = 90 is approximately 0.06
to 0.11; for individuals of average frailty, the difference is more pronounced at 0.342 (0.449
vs. 0.107). We can also conclude that frail patients of either covariate pattern are unlikely
to be in the always-alive state at 90 days. Together, these findings highlight the large
degree to which an individual may be able to tailor their decisionmaking based on additional
information.
4.2.3 Assessment of model fit with discrepancy measures
Figure 3 shows the posterior predictive p-values from the metrics for marginal survival under
treatment (TKM,1,t) and control (TKM,0,t). While the TKM,1 and TKM,0 p-values stay far from
either extreme– indicating adequate fit– the TKS p-value (< 0.001, not shown in figure)
suggests potential misspecification of the underlying frailty distribution. As can be seen in
Figure 3 with TAA,t values near 0.9, this form of misspecification has a moderate impact on
the size of the always-alive population. In particular, the observed sample appears to have
an unusually large proportion in the always-alive state.
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Figure 3: Posterior predictive p-values for three discrepancy measures assessing model fit with
respect to proportion always-alive (TAA), and marginal survival under treatment (TKM,1) and
control (TKM,0)
5 Conclusions
In this paper we have proposed a general approach to principal stratification where the strata
are defined by potential times to a truncating event. From a decisionmaking perspective,
this stratification is a natural one because it groups units according to their time horizon
for comparing quality of life. To quantify those differences, we formulated two new causal
estimands, the TV -SACE and RM -SACE, for contrasting nonterminal time-to-event out-
comes that are truncated by death. We then described a Bayesian model-based estimation
procedure that builds upon existing strategies for semicompeting risks models. Our inno-
vative factorization scheme facilitates connections to existing illness-death models, putting
a sharper causal focus on this literature and clarifying how such models can be adapted to
yield causally interpretable quantities.
The methods outlined here have several limitations that warrant discussion. First, in
our implementation, the latent trait is assumed to be gamma-distributed, and the effect of
the frailty is constrained to be identical across all hazard types and treatment arms. Both
assumptions were made largely for computational convenience because they allow parameter
sampling using the marginal likelihood. Other parametric distributions could be assumed for
the latent trait (e.g., log-normal), and shared frailty models have previously incorporated
transition-specific coefficients for the log-frailty (Liu et al., 2004). These adaptations do
not result in analytically tractable marginal likelihoods, although numerical integration can
be used. In practice, we found MCMC performance using the unmarginalized likelihood
to be inconsistent, slow, and prone to divergent NUTS transitions. Second, the specific
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parametric Weibull hazard models may not be appropriate for all scenarios. More flexible
baseline hazard specifications could be achieved with splines (Royston and Parmar, 2002)
or Bayesian nonparametrics (Lee et al., 2015), although posterior prediction would become
more difficult due to problems extrapolating beyond the observed time scale.
Notwithstanding these limitations, this work offers a new, causally informed approach
to the analysis of semicompeting risks data. Illness-death models pose two challenges for
causal inference on the nonterminal outcome: (1) the use of hazard-based estimation strate-
gies, which implicitly condition on the post-treatment outcome of survival, and (2) handling
truncation when the treatments also affect survival. By formulating causal estimands using
potential outcomes notation, we separate the model estimation from the choice of causal esti-
mand. Our method also indirectly addresses decisionmakers’ need to balance non-mortality
considerations with treatment impacts on survival; this is achieved by quantifying, for every
time point, the relative size of the population for whom quality of life contrasts are relevant.
The use of posterior predictive sampling to estimate the effects allows for the innovative den-
sity factorization which connects to an existing semicompeting risks approach. Analogous
factorizations may prove useful for truncated outcomes which are not time-to-event. Lastly,
because we operate in the Bayesian framework, we properly account for uncertainty due to
partial identifiability of the causal effects.
Future work on these and other principal stratification models for quality of life outcomes
in high-mortality settings may be extended to incorporate utility functions within a formal
decision-theoretic framework. These methods open up more possibilities for causally valid
research on non-mortality outcomes related to quality of life among high-mortality patient
populations. In turn, this provides evidence that is more directly useful to the individuals
and policymakers who must balance considerations of survival and quality of life.
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Supplementary Materials
A Additional details on the prior specification
For binary covariates and continuous variables rescaled to have unit variance, hazard ratios
are unlikely to exceed 5; therefore we set pi(βzj) to be N (0, 2.52) for j = 1, 2, 3 and z = 0, 1.
With mean-centered covariates and αzj = 1, the baseline hazard κ
z
j corresponds to the hazard
experienced by those at the sample mean covariate values. Thus, reasonable priors for the
log-baseline hazards are N (log(Ej/PTj), (log(100)/2)2), where Ej is the number of observed
events and PTj is the total at-risk person-time for transition j, pooling across treatment
arms. For exponential hazards, this prior asserts that the true hazard experienced at the
sample mean value has only ≈ 5% probability of being more than two orders of magnitude
away from the crude (pooled) event rate. The data-driven prior specification for the log-
baseline hazards makes the model invariant to the time scale of the data (i.e., days vs. years).
(An alternative approach would be to rescale all times so that the mean event times were
≈ 1.) Lastly, the Weibull shape parameters (α01, . . . , α13) are given LogNormal(0, 22) priors
to express moderate belief that any changes in the hazards occur slowly rather than quickly
decaying or exploding. Assuming variation independence of the different parameter blocks
β, α, and κ, we can construct a prior as
pi(θ) = pi(β)pi(α)pi(κ) (7)
B Marginalization of conditional likelihood Lc over frail-
ties γ
Let λj(t|·) be the instantaneous hazards and Λj(t|·) be the cumulative hazards for transition
j ∈ {1, 2, 3}. Then the conditional likelihood contribution of individual i is
Lc,i =[λZi1 (yRi |xi, γi,θ)]δ
R
i [λZi2 (y
R
i |xi, γi,θ)]δ
T
i (1−δRi )[λZi3 (y
T
i |yRi ,xi, γi,θ)]δ
T
i δ
R
i
× exp{−ΛZi1 (yRi |xi, γi,θ)− ΛZi2 (yRi |xi, γi,θ)− ΛZi3 (yTi |yRi ,xi, γi,θ)} (8)
with f(γ|σ) = ∏ni=1 [σ1/σΓ(σ−1)]−1 γ1/σ−1i exp {−γi(1/σ)}, as in the main text. The
marginal likelihood across all observations can be written as
Lm =
n∏
i=1
(∫ ∞
0
Lc,if(γi|σ)dγi
)
≡
n∏
i=1
Lm,i (9)
This was first stated in Xu et al. (2010), but we provide a proof here.
First, we define some shorthand notation to suppress indexing that is unnecessary for
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this proof:
h1 =λ
Zi
1 (y
R
i |xi, γi,θ)
h2 =λ
Zi
2 (y
R
i |xi, γi,θ)
h3 =λ
Zi
3 (y
T
i |yRi ,xi, γi,θ)
H1 =Λ
Zi
1 (y
R
i |xi, γi,θ)
H2 =Λ
Zi
2 (y
R
i |xi, γi,θ)
H3 =Λ
Zi
3 (y
T
i |yRi ,xi, γi,θ)
s =σ
de =δ
E
i for E ∈ {R, T}
g =γi
and note a general property of the gamma function that for k ∈ R+
Γ(k + 1) = kΓ(k) (10)
Lm,i =
∫ ∞
0
g1/s−1
s1/sΓ(1/s)
hdr1 h
dt(1−dr)
2 h
drdt
3 exp {−H1 −H2 −H3 − g/s} dg
=
s−1/sΓ(1/s+ dr + dt)hdr1 h
dt(1−dr)
2 h
drdt
3 (1/s+H1 +H2 +H3)
−1/s−dr−dt
Γ(1/s)
=
Γ(1/s+ dr + dt)
Γ(1/s)
× hdr1 hdt(1−dr)2 hdrdt3 × s(dr+dt) s−1/s−dr−dt (1/s+H1 +H2 +H3)−1/s−dr−dt︸ ︷︷ ︸
(1+s(H1+H2+H3))
−1/s−dr−dt
=hdr1 h
dt(1−dr)
2 h
drdt
3 × (1 + s)drdt︸ ︷︷ ︸
(sdr+dt)Γ(1/s+dr+dt)Γ(1/s) for the relevant (dr,dt)
× (1 + s(H1 +H2 +H3))−1/s−dr−dt
To see the final line, consider the 4 possible values taken on by the binary indicators
(dr, dt):
Case 1: (dr, dt) = (0, 0)
1 = (1 + s)0 =s(0+0)
Γ(1/s)
Γ(1/s)
= 1
Cases 2 and 3: (dr, dt) = (0, 1) and (1, 0)
1 = (1 + s)0 =
s1Γ(1/s+ 1)
Γ(1/s)
= 1
where the rightmost equality is true by Equation 10.
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Case 4: (dr, dt) = (1, 1)
s1+1
Γ(1/s+ 1 + 1)
Γ(1/s)
=s(1/s)−1
Γ(1/s+ 2)
Γ(1/s+ 1)︸ ︷︷ ︸
1/s+1 by 10
Γ(1/s+ 1)
Γ(1/s)
=s(1/s+ 1)× Γ(1/s+ 1)
(1/s)Γ(1/s)︸ ︷︷ ︸
1 by 10
=s+ 1
This proves the marginal likelihood has the form stated in the main text:
Lm =
n∏
i=1
[
(1 + σ)δ
R
i δ
T
i [λZi1 (y
R
i |xi,θ)]δ
R
i [λZi2 (y
R
i |xi,θ)]δ
T
i (1−δRi )[λZi3 (y
T
i |yRi ,xi,θ)]δ
T
i δ
R
i
×
(
1 + σ
[
ΛZi1 (y
R
i |xi,θ) + ΛZi2 (yRi |xi,θ) + ΛZi3 (yTi |yRi ,xi,θ)
])−(1/σ+δRi +δTi )]
C Log-likelihood contributions by observed data pat-
tern
The log-likelihood marginalized over the frailties is
`mi = δ
R
i δ
T
i
(
log (1 + σ)+log(λ3)
)
+δRi log(λ1)+δ
T
i (1−δRi ) log(λ2)−(1/σ+δRi +δTi ) log(1+B)
with B = σ(Λ1 + Λ2 + Λ3). This is the likelihood that gets added to the target function
within Stan.
The marginal likelihood Lm in the main text corresponds to 4 types of marginal likelihood
and log-likelihood contributions: (1) neither event occurrence, (2) nonterminal occurrence
only, (3) terminal occurrence only, and (4) both event occurrence.
1. Observe neither event (δRi = δ
T
i = 0)
Lmi =
(
1 + σ
[
ΛZi1 (y
R
i |xi,θ) + ΛZi2 (yRi |xi,θ)
])−(1/σ)
`mi =− (1/σ) log
(
1 + σ
[
ΛZi1 (y
R
i |xi,θ) + ΛZi2 (yRi |xi,θ)
])
=− (1/σ) log
(
1 + σ
[
κZi1 e
x′iβ
z
1(yRi )
α
Zi
1 + κZi2 e
x′iβ
z
2(yRi )
α
Zi
2
])
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2. Observe only nonterminal (δRi = 1, δ
T
i = 0)
Lmi =λZi1 (yRi |xi,θ)
(
1 + σ
[
ΛZi1 (y
R
i |xi,θ) + ΛZi2 (yRi |xi,θ) + ΛZi3 (yTi |yRi ,xi,θ)
])−(1/σ+1)
`mi = log
(
λZi1 (y
R
i |xi,θ)
)
+
− (1/σ + 1) log (1 + σ [ΛZi1 (yRi |xi,θ) + ΛZi2 (yRi |xi,θ) + ΛZi3 (yTi |yRi ,xi,θ)])
= log
(
κZi1 α
Zi
1 e
x′iβ
z
2(yRi )
α
Zi
1
)
+
− (1/σ + 1) log
(
1 + σ
[
κZi1 e
x′iβ
Zi
1 (yRi )
α
Zi
1 + κZi2 e
x′iβ
Zi
2 (yRi )
α
Zi
2 + κZi3 e
x′iβ
Zi
3 (yTi − yRi )α
Zi
3
])
3. Observe only terminal (δRi = 0, δ
T
i = 1)
Lmi =λZi2 (yRi |xi,θ)
(
1 + σ
[
ΛZi1 (y
R
i |xi,θ) + ΛZi2 (yRi |xi,θ)
])−(1/σ+1)
`mi = log
(
λZi2 (y
R
i |xi,θ)
)
+
− (1/σ + 1) log (1 + σ [ΛZi1 (yRi |xi,θ) + ΛZi2 (yRi |xi,θ)])
= log
(
κZi2 α
Zi
2 e
x′iβ
Zi
2 (yRi )
α
Zi
2
)
+
− (1/σ + 1) log
(
1 + σ
[
κZi1 e
x′iβ
Zi
1 (yRi )
α
Zi
1 + κZi2 e
x′iβ
Zi
2 (yRi )
α
Zi
2
])
4. Observed both events (δRi = δ
T
i = 1)
Lmi =(1 + σ)λZi1 (yRi |xi,θ)λZi3 (yTi |yRi ,xi,θ)×(
1 + σ
[
ΛZi1 (y
R
i |xi,θ) + ΛZi2 (yRi |xi,θ) + ΛZi3 (yTi |yRi ,xi,θ)
])−(1/σ+δRi +δTi )
`mi = log (1 + σ) + log
(
λZi1 (y
R
i |xi,θ)
)
+ log
(
λZi3 (y
T
i |yRi ,xi,θ)
)
+
− (1/σ + 2) log (1 + σ [ΛZi1 (yRi |xi,θ) + ΛZi2 (yRi |xi,θ) + ΛZi3 (yTi |yRi ,xi,θ)])
= log (1 + σ) + log
(
κZi1 α
Zi
1 e
x′iβ
Zi
1 (yRi )
α
Zi
1
)
+ log
(
κZi3 α
Zi
3 e
x′iβ
Zi
3 (yTi − yRi )α
Zi
3
)
+
− (1/σ + 2) log
(
1 + σ
[
κZi1 e
x′iβ
Zi
1 (yRi )
α
Zi
1 + κZi2 e
x′iβ
Zi
2 (yRi )
α
Zi
2 + κZi3 e
x′iβ
Zi
3 (yTi − yRi )α
Zi
3
])
D Frailty marginalization and posterior predictive im-
putation
D.1 Full conditional form of frailties
Omitting terms which do not depend on γi, the conditional likelihood as a function of γi is
Lc ∝ γiδRi +δTi exp
{−γi [Λ1(yRi |xi,θ) + Λ2(yRi |xi,θ) + Λ3(yTi |yRi ,xi,θ)+]}
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This demonstrates that the posterior distribution of γi, conditional on θ, only depends on
the data through Oi. The only other place γi appears in the posterior is in f(γi|σ), which
has kernel γi
1/σ−1 exp{−γi(1/σ)}. Thus, the full conditional distribution for γi is
pi(γi|·) ∝ γi1/σ+δRi +δTi −1 exp
{−γi [1/σ + Λ1(yRi |xi,θ) + Λ2(yRi |xi,θ) + Λ3(yTi |yRi ,xi,θ)]}
which can be recognized as the kernel of a Gamma(a1, a2) with a1 = 1/σ + δ
R
i + δ
T
i and
a2 = 1/σ + Λ1(y
R
i |xi,θ) + Λ2(yRi |xi,θ) + Λ3(yTi |yRi ,xi,θ).
D.2 Frailty imputation
For each i = 1, . . . , n and b = 1, . . . , B, sample γi
(b) as
γi
(b)|θ(b) ∼ Gamma
(
1/σ + δRi + δ
T
i , 1/σ + Λ1(y
R
i |xi,θ(b)) + Λ2(yRi |xi,θ(b)) + Λ3(yTi |yRi ,xi,θ(b))
)
D.3 Sampling from the posterior predictive distribution
D.3.1 Imputation of censored outcomes
Censoring is the cause of missing outcome data in the factual treatment arm. In the
presence of censoring for individual i, there is only partial information on one or both of
(Ri(Zi), Ti(Zi)). Given censoring time Ci and draw b of the posterior parameter and frailty
vectors (θ(b), γi
(b)), we can impute R
(b)
i (Zi) or
(
R
(b)
i (Zi), T
(b)
i (Zi)
)
. The hazards specified in
the main text lead to a simple imputation strategy based on Weibull random deviates. The
resulting draws of
(
R
(b)
i (Zi), T
(b)
i (Zi)
)
are compatible with θ(b), γ
(b)
i , and Oi. If individual
i was censored before the nonterminal event occurred, we impute the missing event times
according to the following algorithm.
1. Impute a candidate nonterminal event time R∗ from a Weibull distribution with shape
parameter α
Zi,(b)
1 and scale parameter exp
{
−(log(γi(b)κZi,(b)1 ) + x′iβZi,(b)1 )/αZi1
}
that is
truncated to have no mass below Ci.
2. Impute a candidate death time T ∗ from a Weibull distribution with shape parameter
α
Zi,(b)
2 and scale parameter exp
{
−(log(γi(b)κZi,(b)2 ) + x′iβZi,(b)2 )/αZi,(b)2
}
that is trun-
cated to have no mass below Ci. If T
∗ < R∗, set Ri(Zi)(b) = R¯ and Ti(Zi)(b) = T ∗.
This gives us a complete (Ri(Zi)
(b), Ti(Zi)
(b)) and the imputation process concludes.
Otherwise, set Ri(Zi)
(b) = R∗ and continue to Step 3.
3. Impute a sojourn time S∗ from a Weibull distribution with shape parameter αZi,(b)3 and
scale parameter exp
{
−(log(γi(b)κZi,(b)3 ) + x′iβZi,(b)3 )/αZi,(b)3
}
.
4. Set the imputed death time Ti(Zi)
(b) to Ri(Zi)
(b) + S∗.
For individuals censored after the nonterminal event, the procedure starts at Step 3 with the
modification that the distribution of the sojourn time must be truncated to have no mass
below Ci − Ri(Zi). After imputation, each individual has a complete set of four potential
outcomes for all B MCMC iterations.
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D.3.2 Imputation of counterfactual potential outcomes
Missingness in the outcome pair (Ri(1− Zi), Ti(1− Zi)) is due to the so-called fundamental
problem of causal inference. From assuming independent gamma-distributed frailties as in
the main text, we have that posterior draws of
(
R
(b)
i (1− Zi), T (b)i (1− Zi)
)
depend only on
γ
(b)
i , θ
(b), and Oi.
Imputation of outcomes in the treatment arm counter to fact is actually simpler be-
cause there is no need to truncate so that the imputed values agree with the observed
(Y Ri , δ
R
i , Y
T
i , δ
T
i ). Replace Zi with 1 − Zi and Ci with 0, then follow the algorithm in Sec-
tion D.3.1.
E Discrepancy metrics
Here we outline the algorithms for the calculation of posterior predictive p-values from two
relevant discrepancy measures.
E.1 Proportion always-alive
For b = 1, . . . , B post-warmup draws of θ from the posterior distribution and i = 1, . . . , n:
1. Draw frailty γ
rep(b)
i
i.i.d∼ Gamma (1/σ(b), 1/σ(b)).
2. Set Zrepi = Z
obs
i , C
rep
i = C
obs
i , and X
rep
i = X
obs
i .
3. Simulate replicate uncensored factual potential outcomes R
rep(b)
i (Zi) and T
rep(b)
i (Zi)
and counter-to-fact potential outcomes R
rep(b)
i (1 − Zrepi ) and T rep(b)i (1 − Zrepi ) using
Xrepi ,θ
(b), and γ
rep(b)
i .
4. Apply censoring time Crepi to obtain(
Y
R,rep(b)
i (Z
obs
i ), δ
R,rep(b)
i (Z
obs
i ), Y
T,rep(b)
i (Z
obs
i ), Y
R,rep(b)
i (1− Zobsi ), Y T,rep(b)i (1− Zobsi )
)
5. Determine principal states at tk for k = 1, . . . , K:
V
rep(b)
i (tk) =

AA Y
T,rep(b)
i (1) > tk, Y
T,rep(b)
i (0) > tk
TK Y
T,rep(b)
i (1) ≤ tk, Y T,rep(b)i (0) > tk
CK Y
T,rep(b)
i (1) > tk, Y
T,rep(b)
i (0) ≤ tk
DD Y
T,rep(b)
i (1) ≤ tk, Y T,rep(b)i (0) ≤ tk
6. Calculate replicate fraction always-alive at time tk, V¯
rep,(b)
AA,tk
V¯
rep,(b)
AA,tk
= n−1
n∑
i=1
1
(
V
rep(b)
i (tk) = AA
)
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7. Calculate corresponding fraction in the observed data set, V¯
obs,(b)
AA,tk
V¯
obs,(b)
AA,tk
= n−1
n∑
i=1
1
(
V
obs(b)
i (tk) = AA
)
8. Calculate discrepancy measure T
(b)
AA,tk
= 1
(
V¯
obs,(b)
AA,tk
> V¯
rep,(b)
AA,tk
)
.
The posterior predictive p-value at tk for the discrepancy measure is PPPVAA,tk = B
−1∑B
b=1 T
(b)
AA,tk
.
E.2 Marginal survival within treatment arms
The algorithm is identical to the one in Section E.1 through Step 5. Then, for each z ∈ {0, 1}
at a series of time points t ∈ {t1, . . . , tK}:
5. Using the observed data, calculate the marginal Kaplan-Meier survival estimate in arm
z at a grid of K times t1, . . . , tK , where tK is the maximum observed event or censoring
time in the observed data. For the Dobs unique observed death times, let τ obsm be the
mth observed ordered event time (m = 1, . . . , Dobs). Denote the number of deaths
occurring at time t in the Z = z group by dobsz (t), and the number at-risk at time t in
the Z = z group by robsz (t).
KM obsz (tk) =
∏
m:τobsm <tk
[
1− d
obs
z (τ
obs
m )
robsz (τ
obs
m )
]
This does not depend on θ and is therefore the same across all b = 1, . . . , B.
6. For the replicate data set corresponding to bth MCMC iteration, let Drep,b denote the
unique replicate death times, let τm be the m
th replicate event time (m = 1, . . . , Drep,b).
KM repz (tk) =
∏
m:τm<tk
[
1− d
rep
z (τm)
rrepz (τm)
]
7. Calculate discrepancy measure in T
(b)
KM,z,tk
= 1
(
KM obsz (tk) > KM
rep
z (tk)
)
.
The posterior predictive p-value at tk for the marginal survival discrepancy measure in group
z is PPPVKM,z,tk = B
−1∑B
b=1 T
(b)
KM,z,tk
.
E.3 Kolmogorov-Smirnov deviation from gamma frailty
2. Calculate the Kolmogorov-Smirnov (KS) test statistic as the maximum deviation of
the empirical CDF of the replicate frailties Fˆ
rep(b)
n (x) from F (b)(x;σ(b)), the CDF of the
gamma distribution with mean 1 and variance σ(b):
KSrep(b) = max
x∈(0,∞)
∣∣∣Fˆ rep(b)n (x)− F (b)(x;σ(b))∣∣∣
= max
x∈(0,∞)
∣∣∣∣∣∣n−1
n∑
i=1
(
γ
rep(b)
i < x
)
−
γ
(
σ−1(b), σ−1(b)x
)
Γ
(
σ−1(b)
)
∣∣∣∣∣∣
where γ (x; a) is the lower incomplete gamma function and Γ(a) is the gamma function.
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3. Calculate the corresponding KS statistic for the imputed frailties in the observed data:
KSobs(b) = max
x∈(0,∞)
∣∣∣Fˆ obs(b)n (x)− F (b)(x;σ(b))∣∣∣
= max
x∈(0,∞)
∣∣∣∣∣∣n−1
n∑
i=1
(
γ
obs(b)
i < x
)
−
γ
(
σ−1(b), σ−1(b)x
)
Γ
(
σ−1(b)
)
∣∣∣∣∣∣
4. Calculate discrepancy measure T
(b)
KS = 1
(
KSobs(b) > KSrep(b)
)
.
The posterior predictive p-value for the KS discrepancy measure is PPPVKS = 1−B−1
∑B
b=1 T
(b)
KS.
Subtracting from 1 ensures that B−1
∑B
b=1 T
(b)
KS closer to 1 (i.e., because of poor fit) corre-
spond to p-values closer to 0, as with conventional frequentist p-values.
F Data application: frailties
Figure 4 shows density of posterior draws for γ for the 6,840 in-sample individuals in red.
The blue density shows the posterior predictive distribution implied by the posterior of
σ (i.e., the distribution of γi for a new individual). The relative excess of frailties < 1
suggests that the individuals in the sample are healthier than expected by the model. This
suggests that the gamma distribution may not be a good choice for the frailties, although
this may be alleviated by more flexible specification of baseline hazards or covariate effects.
Since the frailty is a driver of correlation in survival status across treatment arms, this form
of misspecification for the frailty may explain the high p-values we observed for the TAA
discrepancy metric.
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Figure 4: Density of in-sample posterior predictive frailties compared to the samples from
the posterior predictive distribution of latent frailties implied by σ
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